TNFR2: Target for therapeutics against neurodegenerative diseases?

Ingrid M. Nijholt; Ivica Granic; Paul G. M. Luiten; Ulrich L. M. Eisel

doi:10.1007/978-1-4419-6612-4_59

TNFR2: Target for therapeutics against neurodegenerative diseases?

Ingrid M. Nijholt^*
, Ivica Granic
, Paul G. M. Luiten
, Ulrich L. M. Eisel

^*Corresponding author for this work

Eisel lab - Molecular Neurobiology and Neuroimmunology

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › Academic › peer-review

4 Citations (Scopus)

Abstract

Tumor necrosis factor α (TNFα) is a proinflammatory cytokine which acts via its two receptors TNFR1 and TNFR2. It is involved in many cell types in various cellular functions of cell growth, differentiation, and cellular apoptosis. Whereas soluble TNF has the highest affinity for TNFR1 and is therefore its main activator, the membrane standing precursor form of TNF was found to be the strongest activator of TNFR2. This may be also the simple technical reason why for a very long time hardly any TNFR2-specific response was known. In fact for a very long time TNFR2 was believed to function as ligand-passing receptor to TNFR1 or to be just a costimulator of TNFR1 signaling events. In fact under certain conditions this might be true yet a specific and TNFR1-independent signaling role was until recently not established [24].

Original language	English
Title of host publication	Advances in TNF Family Research
Subtitle of host publication	Proceedings of the 12th International TNF Conference, 2009
Editors	D Wallach, A Kovalenko, M Feldman
Place of Publication	Berlin
Publisher	Springer
Chapter	59
Pages	567-573
Number of pages	7
ISBN (Print)	978-1-4419-6611-7
DOIs	https://doi.org/10.1007/978-1-4419-6612-4_59
Publication status	Published - 2011
Event	12th Biennial International TNF Conference - San Lorenzo del Escorial, Spain Duration: 26-Apr-2009 → 29-Apr-2009

Publication series

Name	Advances in Experimental Medicine and Biology
Publisher	Springer Verlag Berlin
Volume	691
ISSN (Print)	0065-2598

Conference

Conference	12th Biennial International TNF Conference
Country/Territory	Spain
City	San Lorenzo del Escorial
Period	26/04/2009 → 29/04/2009

Keywords

FACTOR-KAPPA-B
GLUTAMATE-INDUCED EXCITOTOXICITY
CA2+-ACTIVATED K+ CHANNELS
POTASSIUM CHANNEL
SMALL-CONDUCTANCE
SIGNALING PATHWAYS
MOUSE-BRAIN
NEUROPROTECTION
ISOFORM
SK2

Access to Document

10.1007/978-1-4419-6612-4_59

TNFR2 Target for therapeutics against neurodegenerative diseasesFinal publisher's version, 513 KBLicence: Taverne

Handle.net

Persistent link

Cite this

Nijholt, I. M., Granic, I., Luiten, P. G. M., & Eisel, U. L. M. (2011). TNFR2: Target for therapeutics against neurodegenerative diseases? In D. Wallach, A. Kovalenko, & M. Feldman (Eds.), Advances in TNF Family Research: Proceedings of the 12th International TNF Conference, 2009 (pp. 567-573). (Advances in Experimental Medicine and Biology; Vol. 691). Springer. https://doi.org/10.1007/978-1-4419-6612-4_59

@inproceedings{7d07e1605b05423d84e2f6ecf31b9fbf,

title = "TNFR2: Target for therapeutics against neurodegenerative diseases?",

abstract = "Tumor necrosis factor α (TNFα) is a proinflammatory cytokine which acts via its two receptors TNFR1 and TNFR2. It is involved in many cell types in various cellular functions of cell growth, differentiation, and cellular apoptosis. Whereas soluble TNF has the highest affinity for TNFR1 and is therefore its main activator, the membrane standing precursor form of TNF was found to be the strongest activator of TNFR2. This may be also the simple technical reason why for a very long time hardly any TNFR2-specific response was known. In fact for a very long time TNFR2 was believed to function as ligand-passing receptor to TNFR1 or to be just a costimulator of TNFR1 signaling events. In fact under certain conditions this might be true yet a specific and TNFR1-independent signaling role was until recently not established [24].",

keywords = "FACTOR-KAPPA-B, GLUTAMATE-INDUCED EXCITOTOXICITY, CA2+-ACTIVATED K+ CHANNELS, POTASSIUM CHANNEL, SMALL-CONDUCTANCE, SIGNALING PATHWAYS, MOUSE-BRAIN, NEUROPROTECTION, ISOFORM, SK2",

author = "Nijholt, \{Ingrid M.\} and Ivica Granic and Luiten, \{Paul G. M.\} and Eisel, \{Ulrich L. M.\}",

year = "2011",

doi = "10.1007/978-1-4419-6612-4\_59",

language = "English",

isbn = "978-1-4419-6611-7",

series = "Advances in Experimental Medicine and Biology",

publisher = "Springer",

pages = "567--573",

editor = "D Wallach and A Kovalenko and M Feldman",

booktitle = "Advances in TNF Family Research",

note = "12th Biennial International TNF Conference ; Conference date: 26-04-2009 Through 29-04-2009",

}

Nijholt, IM, Granic, I, Luiten, PGM & Eisel, ULM 2011, TNFR2: Target for therapeutics against neurodegenerative diseases? in D Wallach, A Kovalenko & M Feldman (eds), Advances in TNF Family Research: Proceedings of the 12th International TNF Conference, 2009. Advances in Experimental Medicine and Biology, vol. 691, Springer, Berlin, pp. 567-573, 12th Biennial International TNF Conference, San Lorenzo del Escorial, Spain, 26/04/2009. https://doi.org/10.1007/978-1-4419-6612-4_59

TNFR2: Target for therapeutics against neurodegenerative diseases? / Nijholt, Ingrid M.; Granic, Ivica; Luiten, Paul G. M. et al.
Advances in TNF Family Research: Proceedings of the 12th International TNF Conference, 2009. ed. / D Wallach; A Kovalenko; M Feldman. Berlin: Springer, 2011. p. 567-573 (Advances in Experimental Medicine and Biology; Vol. 691).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › Academic › peer-review

TY - GEN

T1 - TNFR2

T2 - 12th Biennial International TNF Conference

AU - Nijholt, Ingrid M.

AU - Granic, Ivica

AU - Luiten, Paul G. M.

AU - Eisel, Ulrich L. M.

PY - 2011

Y1 - 2011

N2 - Tumor necrosis factor α (TNFα) is a proinflammatory cytokine which acts via its two receptors TNFR1 and TNFR2. It is involved in many cell types in various cellular functions of cell growth, differentiation, and cellular apoptosis. Whereas soluble TNF has the highest affinity for TNFR1 and is therefore its main activator, the membrane standing precursor form of TNF was found to be the strongest activator of TNFR2. This may be also the simple technical reason why for a very long time hardly any TNFR2-specific response was known. In fact for a very long time TNFR2 was believed to function as ligand-passing receptor to TNFR1 or to be just a costimulator of TNFR1 signaling events. In fact under certain conditions this might be true yet a specific and TNFR1-independent signaling role was until recently not established [24].

AB - Tumor necrosis factor α (TNFα) is a proinflammatory cytokine which acts via its two receptors TNFR1 and TNFR2. It is involved in many cell types in various cellular functions of cell growth, differentiation, and cellular apoptosis. Whereas soluble TNF has the highest affinity for TNFR1 and is therefore its main activator, the membrane standing precursor form of TNF was found to be the strongest activator of TNFR2. This may be also the simple technical reason why for a very long time hardly any TNFR2-specific response was known. In fact for a very long time TNFR2 was believed to function as ligand-passing receptor to TNFR1 or to be just a costimulator of TNFR1 signaling events. In fact under certain conditions this might be true yet a specific and TNFR1-independent signaling role was until recently not established [24].

KW - FACTOR-KAPPA-B

KW - GLUTAMATE-INDUCED EXCITOTOXICITY

KW - CA2+-ACTIVATED K+ CHANNELS

KW - POTASSIUM CHANNEL

KW - SMALL-CONDUCTANCE

KW - SIGNALING PATHWAYS

KW - MOUSE-BRAIN

KW - NEUROPROTECTION

KW - ISOFORM

KW - SK2

U2 - 10.1007/978-1-4419-6612-4_59

DO - 10.1007/978-1-4419-6612-4_59

M3 - Conference contribution

SN - 978-1-4419-6611-7

T3 - Advances in Experimental Medicine and Biology

SP - 567

EP - 573

BT - Advances in TNF Family Research

A2 - Wallach, D

A2 - Kovalenko, A

A2 - Feldman, M

PB - Springer

CY - Berlin

Y2 - 26 April 2009 through 29 April 2009

ER -

Nijholt IM, Granic I, Luiten PGM, Eisel ULM. TNFR2: Target for therapeutics against neurodegenerative diseases? In Wallach D, Kovalenko A, Feldman M, editors, Advances in TNF Family Research: Proceedings of the 12th International TNF Conference, 2009. Berlin: Springer. 2011. p. 567-573. (Advances in Experimental Medicine and Biology). doi: 10.1007/978-1-4419-6612-4_59

TNFR2: Target for therapeutics against neurodegenerative diseases?

Abstract

Publication series

Conference

Keywords

Access to Document

Handle.net

Fingerprint

Cite this